StratifiCare™ was founded in 2015 with the vision of empowering personalized medicine for tomorrow through our innovative diagnostic solutions. Due to the lack of advanced medical technology, physicians find it hard to provide individualized treatment for patients. This may result in less optimal clinical outcomes and usage of healthcare resources. By developing technologically advanced in vitro diagnostic solutions, we transform the way patients are managed through personalized care and create value for all.
We develop quality, innovative diagnostic tests to enable healthcare providers in delivering personalized curative therapies to every patient.
StratifiCare™ is committed to contribute to a sustainable healthcare system, and be ethical in the development and deployment of our diagnostic tests.
Social Development Goal
As a responsible medical technology provider, StratifiCare adopts the SDG framework. By developing quality, innovative diagnostic solutions, we pledge to facilitate access to quality essential health services, for the general and the most disadvantaged population.
StratifiCare is proud to be a signatory of the EPiHC, and we are committed to promote ethical decision-making and behaviour in health services by following the EPiHC's set of 10 principles.
StratifiCare™ efforts in improving patient care are recognized and our quality management system has been certified to international standards.
StratifiCare won the DBS Foundation Social Impact Prize, which is awarded to the most innovative business plans / start-ups / early-stage ventures that address pertinent urban challenges faced by cities of today.
StratifiCare is one of the few medtech startups in Singapore who achieved the
ISO 13485:2016 certification, showing that our quality management system adheres to the highest international standards for the design and development of in vitro diagnostic tests.
Meet the Team
Chief Executive Officer
Anthony obtained his PhD in Virology from the National University of Singapore (NUS), and is an alumnus of the NUS Overseas College. He was trained in high-tech entrepreneurship at the University of Pennsylvania and later, at INSEAD. Since 2006, he has been involved with numerous BioTech/MedTech startups and tech transfer offices both locally and internationally. Anthony’s work contributed to the acquisition of Protez Pharmaceuticals by Novartis, and together with Professor Mary Ng, played instrumental roles in attracting Fujitsu Laboratories Limited to establish their very first BioTech research facility in Singapore.
Chief Operating Officer
As COO, Keith focuses on the background IP protection and product commercialization. He has received a PhD in Virology from National University of Singapore (NUS). Earlier, he has been working with Dengue virus for 7 years to identify viral-host interacting partners. Throughout his career in the industry, Keith has experience with introducing new technologies to customers and provide strategic partnership in a multinational life science company.
Chief Scientific Advisor
Professor Ng is an internationally renowned scientist with more than 30 years of in-depth experience in Virology research. Being among the first to study the replication cycle of the SARS virus, she is the scientist behind the acclaimed SARS virus scanning electron micrograph showcased by the Smithsonian National Museum of Natural History, CDC, National Geographic and CNN. Professor Ng was a member of the WHO Advisory Committee on Dengue and other Flavivirus Vaccines, and the advisor to the Novartis Institute of Tropical Diseases. She has collaborated with numerous BioTech/MedTech companies, including MP Biomedicals, Fujitsu Laboratories / Adaptamer Solutions, Austrianova Singapore etc., and is the inventor of 7 patents to date.
Chief Regulatory Officer
Prior to joining StratifiCare™, Tiffany was one of the main drivers of a Singapore-based cross-institutional effort to design and develop a cost-effective microfluidic diagnostic platform using gold nanoparticles for infectious disease testing. Tiffany is a certified Lead Auditor for ISO 13485 by the British Standards Institute, and spearheads the quality management system at StratifiCare™, to ensure safety and quality are built into each product.
Chief Marketing Officer
Jennifer has more than 20 years of B2B/B2C working experience in pharmaceutical APIs, CDMO and biotech spaces for Asia Pacific markets, with strong track record in business development and strategic partnership with key customers & government authorities. She had taken leadership and strategic positions in global multinational companies and start-up companies, and was the Vice President, Asia at Seqens Asia Pacific Limited. She had managed numerous projects on M&A deals, due diligence, post-merger integration, greenfield project and digital transformation projects. Jennifer graduated with an MBA from the University of Hull in UK, and a BSc in Chemistry from Imperial College London.
Board of Advisors
Leesa is a serial entrepreneur with over 20 years of experience in cutting edge of innovation, technology and strategy consulting. To date, Leesa has advised more than 400 multinationals and start-ups in 19 sectors across Europe, Asia-Pacific and the Americas, and led companies from Seed to $14B USD into new markets. Her work in strategy, reputation, risk, and technology has enabled companies with proven strategies, tools and technologies to acquire, protect and support their licenses to operate, mitigate risks and exploit opportunities for accelerated market access and revenue growth. Leesa holds expert industry expertise in deep technology, insurance, fintech, healthcare and pharmaceutical sectors.
Edward (Ted) Ruppel
Ted Ruppel, President and CEO of Shape Memory Medical Inc., brings more than 25 years of entrepreneurial and medical device company management experience, including the IPO of Micrus Endovascular Corp. Ted was formerly EVP/CFO of Vascular Dynamics and Senior VP of R&D and Operations at Micrus Endovascular Corporation (acquired by J&J). He held previous management/operations roles at CBYON Inc., Biometric Imaging (acquired by BD), Applied Biosystems, and Spectra-Physics. Ted has a BSME from the University of Rochester and MBA (TRIUM - Jointly conferred by London School of Economics and Political Science, NYU Stern School of Business, and HEC Paris).
Professor Ignatius Rasiah has over 25 years of experience in R&D management of product development in the industry and has held numerous key advisory and membership positions at national agencies, such as the National Lung Cancer Taskforce in Malaysia and the SG Tech Panel at Enterprise Singapore.
Prof. Rasiah is currently the Program Director at the Institute for Engineering Leadership, National University of Singapore. He was also the CTO at Perkin Elmer Optoelectronics and the VP for Breakthrough Research at Medtronic where his work focused on breakthrough technologies and business models relating to the surgical and patient monitoring spaces.